Sequential Regimen of Bendamustin-Debulking Followed by Obinutuzumab, Acalabrutinib and Venetoclax in Patients With Relapsed/Refractory CLL
Clinical trial NCT03787264 · COMPLETED
Trial details
- NCT number
- NCT03787264
- Sponsor
- German CLL Study Group
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2019-01-14
- Primary completion
- 2021-02-11
- Enrollment
- 46
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.